OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Malignant Pleural EffusionPleural NeoplasmsQuality of LifeChemotherapy EffectChemotherapeutic ToxicityPleural CarcinomatosisPleural Cavity Effusion
Interventions
DRUG

PITAC

Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.

Trial Locations (1)

5000

RECRUITING

Odense PIPAC Center, Department of Surgery, Odense University Hospital, Odense

All Listed Sponsors
lead

Odense University Hospital

OTHER